Lactobacillus gasseri, BNR17™, (hereafter referred to by use of the trademark, BNR17™) is a new probiotic strain with a great deal of potential. This strain, of natural origin, has been shown to support a healthy body mass index and a healthy metabolism and level of abdominal fat.
In addition, the probiotic strain has been shown to support digestive health.
Isolated from human breast milk
The BNR17™ strain, a strain isolated from human breast milk, was scientifically selected from 319 strains for its role in weight support and gastrointestinal wellness. Chr. Hansen licensed the strain in 2018 based on its scientific documentation and future potential.
The probiotic strain BNR17™ has excelled in human trials
The probiotic strain BNR17™ has undergone extensive analysis and has excelled in three high quality human studies.
In one study, the participants taking the BNR17™ strain saw a significant waist circumference decrease. The mean loss in waist circumference was five centimeters over a 12-week consumption period. The placebo group did not change significantly.1
Awards and acknowledgements for the BNR17™ strain
The probiotic strain BNR17™ was named the "2018 Weight Management Ingredient of the Year" by a panel of 15 scientists and industry experts at the inaugural edition of the NutraIngredients-USA Awards.
In addition, the BNR17™ strain is the first probiotic strain supporting healthy levels of abdominal fat individually acknowledged by the Ministry of Food and Drug Safety (KFDA) in South Korea.
BNR17™ is a trademark under license to Chr. Hansen from Bioneer Corporation.
References
1 Jung et al. Korean J Fam Med 2013.
2 Kim et al. J Med Food 2018.
3 Shin et al. J Clin Biochem Nutr 2018.
This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers of final consumer goods. Nothing on this page is meant to be perceived as an approved claim.
